PROGRESS REPORT: SOCIAL MEDIA TOOLKIT
Getting Started:
- Follow us on our social media platforms
- Download our social media cards (“Full Progress Report Cards”) sized for LinkedIn and Twitter.
- Link to Report on our website: https://bit.ly/3BTSZa4
- Please consider tagging our Progress Report partner, @RANDEurope.
SOCIAL MEDIA MESSAGES
We’ve provided sample messages to help you promote the Progress Report across social media platforms. You can copy and paste the messages below or tailor them to meet your needs.
General
- The life science industry is a crucial partner in efforts to curb #AMR 🦠. Check out the AMR Industry Alliance’s Progress Report for a unique snapshot of the collective efforts against here: https://bit.ly/3BTSZa4 #amrindustryalliance #AntimicrobialResistance
- Proud of our Progress Report launch outlining our collective efforts in the fight against #AMR 🦠 More more here ➡️: https://bit.ly/3BTSZa4 #amrindustryalliance #AntimicrobialResistance
- The 2022 AMR Industry Alliance Progress Report has launched! Learn more about key challenges in fighting this rising global health threat, and what we are doing about it and how we can continue to improve by clicking https://bit.ly/3BTSZa4 ⬅️ #amrindustryalliance #AntimicrobialResistance
- AMR is one of the most significant public health challenges facing society. Mitigating its risks and managing its impacts requires a collective effort.🦠 Check out the 2022 #AMR Industry Alliance Report here ➡️: https://bit.ly/3BTSZa4 #amrindustryalliance #AntimicrobialResistance
Research and Science
- AMRIA Members have invested over USD$4B in #AMR-relevant R&D in the last two years 🔬. These investments cannot be sustained without improvements in the market. Learn more about the AMR Industry Alliance Progress Report ➡️ https://bit.ly/3BTSZa4 #amrindustryalliance #AntimicrobialResistance
- Alliance Members continue to contribute to R&D focused on #AMR priority pathogens with over 93 products or technologies! 🔬Learn more about our collective efforts in the fight against #AMR ➡️https://bit.ly/3BTSZa4#amrindustryalliance #AntimicrobialResistance
Access
- Improving patient access to the right diagnosis, treatment, and vaccines at the right time is a top priority for the #AMRIndustryAlliance. 💊 Learn more about our collective efforts in the fight against #AMR ➡️ https://bit.ly/3BTSZa4 #AntimicrobialResistance
Appropriate Use
- 83% of #AMRIndustryAlliance R&D pharma and 80% of diagnostics report having appropriate use and stewardship strategies or plans for AMR-relevant products and/or technologies. Learn more ➡️ https://bit.ly/3BTSZa4 #AMR #AntimicrobialResistance
- #AMRIndustryAlliance Members are implementing exciting appropriate use and stewardship activities around the world. 🗺️ Learn more about our collective efforts in the fight against #AMR here ➡️ https://bit.ly/3BTSZa4 #AMR #AntimicrobialResistance [Social card available for this key message]
Manufacturing and the Environment
- #AMRIndustryAlliance Members have made significant achievements in implementing Alliance manufacturing requirements. 🏭 Learn more about our collective efforts in the fight against #AMR here ➡️ https://bit.ly/3BTSZa4 #AMR #AntimicrobialResistance
- 98% of #AMRIndustryAlliance company-owned manufacturing sites either fully or partially meet the requirements of the Common Antibiotic Manufacturing Framework, and 87% of products manufactured at these sites meet PNEC Targets. Leading the fight against #AMR ➡️: https://bit.ly/3BTSZa4 #AMR #AntimicrobialResistance
General
- We are thrilled to announce that the 2022 #AMRIndustryAlliance Progress Report has launched. Rising antimicrobial resistance threatens every aspect of modern medicine and underscores the urgency of our mission. Thank you to our Members for their support and collective efforts against #AMR. We know more is still yet to be done in the fight against AMR. Check out the Report here: https://bit.ly/3BTSZa4 #amrindustryalliance #AntimicrobialResistance #antibiotics. The AMRIA report was produced by RAND Europe, a not-for-profit organisation.
- As #AMR grows, our arsenal of antibiotics becomes less and less effective, undermining the foundations of our healthcare systems. We believe that a united industry sector will be able to combat AMR so that 21st century medicine can succeed and progress. However, advancements are at risk if collective action isn’t taken and large-scale incentives are not implemented. Check out the 2022 #AMRIndustryAlliance Progress Report to learn more about what can be done to tackle this rising global health threat. Check out the Report here: https://bit.ly/3BTSZa4 #amrindustryalliance #AntimicrobialResistance #antibiotics The AMRIA report was produced by RAND Europe, a not-for-profit organisation.
- In recognition of the complexity of the challenge presented by #AMR, efforts to tackle the emergence and spread of AMR are being enhanced by governments, international organizations, the life sciences industries, healthcare professionals, academics, not-for-profit organizations, and civil society. Learn more about our collective efforts and paths toward further improvement in the #AMRIndustryAlliance Progress Report here: https://bit.ly/3BTSZa4. #amrindustryalliance #AntimicrobialResistance #antibiotics The AMRIA report was produced by RAND Europe, a not-for-profit organisation.
Research and Science
- AMRIA Members have invested approximately USD$1.8B-1.9B in #AMR-relevant R&D annually in the last two years alone. Though this marks an annual USD$200M increase since 2018 it is not enough. Investment could be at risk of action is not taken to implement better market incentives. We urgently need more sustainable and scalable approaches to incentivizing R&D Learn more about the AMR Industry Alliance by checking out our Progress Report’s here. #AMR #amrindustryalliance #AntimicrobialResistance The AMRIA report was produced by RAND Europe, a not-for-profit organisation.
- Alliance Members continue to contribute to R&D focused on AMR priority pathogens with over 93 products or technologies! These include 54 antibiotics and antifungals, 12 vaccines, 13 diagnostic platforms and assays and 14 non-traditional products. Read our Progress Report here to learn more about the AMR Industry Alliance’s collective efforts. #AMR #amrindustryalliance #AntimicrobialResistance The AMRIA report was produced by RAND Europe, a not-for-profit organisation.
Access
- Improving patient access to the right diagnostics, treatment, and vaccines at the right time is a top priority for the #AMRIndustryAlliance. Over 80% of surveyed companies are actively supporting access to AMR-relevant products and/or technologies with access strategies or plans in place to support such activities. We need to continue to invest in capacity-building to support access and put the spotlight on efforts targeting access to novel and off-patent antibiotics and diagnostics in LMICs. Learn more about the AMR Industry Alliance’s collective efforts by checking out our Progress Report here. #AMR #amrindustryalliance #AntimicrobialResistance The AMRIA report was produced by RAND Europe, a not-for-profit organisation.
Appropriate Use
- #AMRIndustryAlliance Members are implementing exciting appropriate use and stewardship activities around the world. This includes education and awareness-raising, collecting and sharing surveillance data to generate evidence to mitigate inappropriate use of antibiotics and vaccines and improve antimicrobial stewardship. Together we must advocate for enhanced surveillance of AMR through improved data visualization and increase public reporting of infection rates, antibiotic use and mortality rates to support improved stewardship polices and clinical options. Read the AMR Industry Alliance’s Progress Report here to learn more about our collective efforts. #AMR #amrindustryalliance #AntimicrobialResistance The AMRIA report was produced by RAND Europe, a not-for-profit organisation.
Manufacturing and the Environment
- #AMRIndustryAlliance Members have made significant achievements in implementing Alliance manufacturing requirements at manufacturing sites owned by Member companies. This includes Common Antibiotic Manufacturing Framework (CAMF) requirements and Predicted No-effect Concentration (PNEC) Targets. Notably, nearly all manufacturing sites owned by #AMRIndustryAlliance Members meet the Alliance’s CAMF requirements, either in part or in full. We should continue to work towards developing international standards for responsible antibiotic manufacturing to enable buyers to identify responsibly made antibiotics more easily and at the same time drive reductions in antibiotics-manufacturing emissions to ensure environmentally responsible antimicrobial manufacturing. Learn more about our collective efforts in the fight against #AMR here #AMR #AntimicrobialResistance The AMRIA report was produced by RAND Europe, a not-for-profit organisation.
